All In Biotech

Drug Trial Radar · NCT02711345

A Phase I Clinical Study With Investigational Compound LTT462 in Adult Patients With Specific Advanced Cancers.

A Phase I Dose Finding Study of Oral LTT462 in Adult Patients With Advanced Solid Tumors Harboring MAPK Pathway Alterations.

Last checked: Nov 19, 2026Latest source record: Sep 19, 2019 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedResults posted on the registry

Status

Terminated

Enrollment

65

Actual

Start

Apr 15, 2016

Primary completion

Nov 21, 2018

Study completion Nov 21, 2018

Sponsor

Lead sponsor
Novartis PharmaceuticalsNovartis (NVS)
Sponsor type
Industry
First posted
Mar 17, 2016

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 12 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A phase I study of LTT462 in patients with advanced solid tumors that harbor MAPK pathway alterations.

Conditions

  • Ovarian Neoplasms
  • Non-Small-Cell Lung Carcinoma
  • Melanoma
  • Other Solid Tumors

Interventions

  • LTT462Drug

    ERK Inhibitor

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)Time frame: Up to 2.8 years
  2. Percentage of Participants With Dose Limiting Toxicities (DLTs)Time frame: Up to 2.8 years
  3. Percentage of Participants With at Least One Dose ReductionTime frame: Up to 2.8 years
  4. Percentage of Participants With at Least One Dose InterruptionsTime frame: Up to 2.8 years
  5. Dose Intensity Received by ParticipantsTime frame: Up to 2.8 years

Locations

7 sites in 6 countries. Site status is shown where the registry gives one.

  • Novartis Investigative Site

    New York, New York

  • Novartis Investigative Site

    Houston, Texas

  • Novartis Investigative Site

    Essen, Germany

  • Novartis Investigative Site

    Chuo Ku, Tokyo, Japan

  • Novartis Investigative Site

    Singapore, Singapore

  • Novartis Investigative Site

    Barcelona, Catalonia, Spain

  • Novartis Investigative Site

    Bellinzona, Switzerland

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.